ADA supports FDA panel's recommendation for continuing review of existing, new scientific information

The American Dental Association today praised a Food and Drug Administration advisory panel's finding that the FDA acted appropriately when it ruled last year that dental amalgam is a safe and effective treatment option for the general population.  

"The panel recommended continuing review of existing and new scientific information as it becomes available," said ADA President Raymond F. Gist, DDS.  "As a science-based organization representing a science-based profession, we support this."

"As with all clinical issues, our position on amalgam is based on the best available science.  We will continue to maintain or revise our positions on oral health and oral health care issues accordingly.  At the end of the day, all treatment decisions should be made by patients with the advice of their dentists.  We support the rights of all patients to decide how best to maintain and improve their oral health."